Spanish firm Grifols (MCE: GRF) has submitted a Biologics License Application (BLA) for its new potential fibrinogen treatment to the US Food and Drug Administration (FDA). Grifols claims that its ...

An excerpt from yesterday's en banc decision, written by Judge Morgan Christen, in Project Veritas v. Schmidt (reversing the July 2023 panel decision); the full opinions are over 20,000 words long ...

The laboratory diagnosis of DIC is difficult because none of the ... problem due to the consumption of clotting factors and fibrinogen, while few address the issue of activation of the ...

[3] The breakdown of fibrinogen and fibrin results in polypeptides ... which contributes to the bleeding seen with DIC.